Register entry
- Registered sites
- 0
- Active NDC listings
- 1
- Live patents
- 7
- Exclusivities
- 1
- Countries
- 0
Exclusivity
Patents and exclusivities
7| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 12594273 | ATZUMIdihydroergotamine mesylate | product | Sept 2033 |
| 10792253 | ATZUMIdihydroergotamine mesylate | product | Aug 2037 |
| 11872314 | ATZUMIdihydroergotamine mesylate | product | Aug 2037 |
| 10758532 | ATZUMIdihydroergotamine mesylate | product | Dec 2039 |
| 12263162 | ATZUMIdihydroergotamine mesylate | product | Dec 2039 |
| 11744967 | ATZUMIdihydroergotamine mesylate | product | Oct 2041 |
| 12102754 | ATZUMIdihydroergotamine mesylate | product | Oct 2041 |
| Product | Exclusivity | Until |
|---|---|---|
| ATZUMIDIHYDROERGOTAMINE MESYLATE | NP New product | Apr 2028 |
Catalogue
Marketed products
1| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| ATZUMI | DIHYDROERGOTAMINE MESYLATE | powder, nasal | 76978-101NDA |
Compare
Other companies listing dihydroergotamine mesylate
- Curia India Private Limited9 sites · 106 NDC
- Professional Compounding Centers of America dba PCCA1 site · 487 NDC
- Somerset Therapeutics Private Limited1 site · 187 NDC
- MIPHARM SPA1 site · 1 NDC
Enquiry
Common questions
- Is Satsuma Pharmaceuticals, Inc. FDA approved?
- Satsuma Pharmaceuticals, Inc. holds no registered establishment of its own; 1 drug product is listed under its name in the National Drug Code Directory, made at sites registered to other firms.
- What drugs does Satsuma Pharmaceuticals, Inc. make?
- 1 product is listed under Satsuma Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as powder. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.